STOCK TITAN

Aemetis Reports 2023 Fourth Quarter and Year-End Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags
Rhea-AI Summary
Aemetis, Inc. (AMTX) reports $77.2 million in annual sales from the India biodiesel segment, marking a 175% increase over the prior year. The company's total revenue for 2023 was $186.7 million, driven by growth in the biodiesel and renewable natural gas segments. Key financial highlights include a $70.8 million revenue for Q4 2023, repayment of $50.2 million of debt, positive cash flow of $32.7 million, and significant progress in various projects.
Positive
  • Aemetis achieved a substantial increase in annual sales from the India biodiesel segment, reaching $77.2 million, representing a 175% growth year-over-year.
  • The company's total revenue for 2023 amounted to $186.7 million, supported by revenue growth from the biodiesel and renewable natural gas segments.
  • Key financial highlights include a Q4 2023 revenue of $70.8 million, repayment of $50.2 million of debt, positive cash flow of $32.7 million, and progress in several projects outlined in the Five Year Plan.
  • Aemetis also successfully commissioned production capacity by 300% in the Aemetis Biogas segment and closed $50 million of new credit facilities related to USDA guaranteed loans.
Negative
  • None.

The reported 175% increase in annual sales for Aemetis' India biodiesel segment is a significant development, reflecting a robust expansion in a market that is increasingly conscious of renewable energy sources. The growth in revenue to $77.2 million from this segment is a strong indicator of the company's operational success and its ability to capitalize on the rising demand for cleaner fuels. Furthermore, the $5.5 million revenue from the California Renewable Natural Gas segment suggests a diversification of income streams, which is crucial for stability in volatile markets.

However, investors should consider the extended maintenance and upgrade cycle at the Keyes plant, which resulted in a revenue decrease. While this may affect short-term profitability, the long-term benefits of increased efficiency and reduced carbon intensity could lead to improved margins and a stronger competitive position. The capital expenditures of $33 million for 2023, as part of the company's Five Year Plan, indicate a commitment to future growth but also imply a substantial reinvestment of earnings that might affect dividend payments or require additional financing.

Lastly, the repayment of debt and the extension of loan repayment terms, combined with the sale of IRA investment tax credits, suggest a strategic financial restructuring. These moves could improve the company's balance sheet and reduce interest expenses, potentially enhancing shareholder value over time.

The biodiesel and renewable natural gas industries are experiencing a surge in demand, driven by global efforts to reduce carbon emissions. Aemetis' significant sales increase in the India biodiesel segment indicates a strong foothold in a market with considerable growth potential, especially considering India's large population and increasing industrial activity. Moreover, the company's progress in the sustainable aviation fuel (SAF) and renewable diesel plant at Riverbank Industrial Complex, coupled with the 300% increase in Aemetis Biogas commissioned production capacity, positions it well to meet the expected rise in demand for these fuels.

Strategic environmental permits, such as the Use Permit and CEQA and the Authority to Construct air permits, are crucial for the timely execution of expansion projects. These permits also reflect the company's compliance with regulatory standards, which is increasingly important to environmentally conscious investors. As the company expands its biogas pipeline, it is set to benefit from economies of scale, potentially leading to more competitive pricing and increased market share.

The energy sector is in a transition phase, with renewable energy sources like biodiesel and renewable natural gas gaining prominence. Aemetis' investment in carbon intensity reduction and production expansion is timely and aligns with global trends towards sustainability. The investment tax credits from the IRA and the new credit facilities, including USDA guaranteed loans, provide financial support for these initiatives, reducing the risk associated with such capital-intensive projects.

It is important to note that while the company is expanding its production capacity, the actual impact on the stock market will depend on the execution of these projects and the ability to maintain or increase profit margins. The commissioning of new biogas infrastructure is a positive step, but the full financial benefits will only materialize once the projects are fully operational and integrated into the existing energy market.

Investors should be aware of the potential risks associated with the energy sector, such as fluctuating commodity prices and regulatory changes. However, Aemetis' strategic investments and debt management suggest a proactive approach to navigating these challenges.


India biodiesel segment reports $77.2 million of annual sales, an increase of 175% over prior year

CUPERTINO, CA, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWireAemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity products, today announced its financial results for the fourth quarter and twelve months ended December 31, 2023.

“Revenues were $70.8 million for the fourth quarter of 2023, an increase from $66.7 million for the fourth quarter of 2022. Revenues for the full year of 2023 were $186.7 million which includes growth in revenue to $77.2 million from the India Biodiesel segment and $5.5 million from the California Renewable Natural Gas segment, along with the decrease in revenue from the extended maintenance and upgrade cycle at the Keyes plant which allowed for the acceleration of the implementation of several important ethanol plant efficiency upgrades during the historically high natural gas price period in early 2023,” said Todd Waltz, Chief Financial Officer of Aemetis.  “Capital expenditures for carbon intensity reduction and production expansion projects were $33 million for 2023 as our engineering and construction teams moved forward with the initiatives outlined in our Five Year Plan,” added Waltz.

During 2023, Aemetis achieved key milestones, including:

 Repaid $50.2 million of Third Eye Capital debt in Q3 2023, reducing loan balances for the Aemetis Biogas, Aemetis Keyes ethanol plant, Aemetis Riverbank SAF/RD, and Aemetis CCS projects;


 Adjusted EBITDA plus IRA investment tax credit sales generated $32.7 million of positive cash flow during 2023;


 Received the key Use Permit and CEQA last year and recently received the Authority to Construct air permits to build a 90 million gallon per year sustainable aviation fuel and renewable diesel plant at Riverbank Industrial Complex;


 Extended repayment on $108 million of Third Eye Capital debt related to Aemetis Biogas at an effective interest rate of 8.5% for the first four months of 2024;


 Received $55 million from the sale of $63 million of IRA investment tax credits related to qualified biogas project capital expenditures by Aemetis Biogas;

  

 Closed $50 million of new credit facilities related to USDA guaranteed loans, including $25 million of existing credit facilities and $25 million of additional 20-year financing to fund capital expenditures at Aemetis Biogas;


 Increased Aemetis Biogas commissioned production capacity by 300% during 2023;


 Commissioned 36 miles of biogas pipeline, the biogas-to-RNG production facility, and the utility gas interconnection unit;


 Received approval of the CEQA environmental review to extend the biogas pipeline to a total of 60 miles allowing for collection of biogas from an aggregate of about 40 dairies;


 Received approval for the generation of D3 RINs by our Renewable Natural Gas business and completed the first sales of these D3 RINs;


 Received the first CO2 sequestration characterization well permit issued by the State of California to a private company;


 Expanded our India biodiesel production capacity to 60 million gallons per year ahead of schedule; and


 Received allocations for a combined $184 million of biodiesel sales in India for 2023 and the first three quarters of 2024, which we expect to continue as an ongoing fuel supply relationship with the three government-owned oil marketing companies in India.


“In addition to achieving important operational milestones during 2023 in all of our business segments, we closed one new credit facility and refinanced another construction debt facility for an aggregate of $50 million of USDA-guaranteed, 20-year funding to construct dairy digesters,” said Eric McAfee, Chairman and CEO of Aemetis. “We invite investors to review the updated Aemetis Five Year Plan on the Aemetis home page prior to the earnings call.”

Today, Aemetis will host an earnings review call at 11:00 a.m. Pacific time (PT).

Live Participant Dial In (Toll Free): +1-888-506-0062 entry code 971618
Live Participant Dial In (International): +1-973-528-0011 entry code 971618
Webcast URL: https://www.webcaster4.com/Webcast/Page/2211/50051

For the presentation and details on the call, please visit http://www.aemetis.com/investors/conference-calls/.

Financial Results for the Three Months Ended December 31, 2023

Revenues were $70.8 million for the fourth quarter of 2023, an increase from $66.7 million for the fourth quarter of 2022. The ethanol gallons sold increased from 13.4 million gallons during the fourth quarter of 2022 to 15 million gallons during the fourth quarter of 2023. Biodiesel sales of 18.3 thousand metric tons were recorded during the fourth quarter of 2023 at $1,157 per metric ton. Our California Ethanol segment accounted for $45 million of revenues and our India Biodiesel segment accounted for $22 million of revenues during the period.

Cost of Goods Sold increased from $67.9 million during the fourth quarter of 2022 to $69.9 million during the fourth quarter of 2023, due to 18% increase in feedstock costs from the incremental sales in our India Biodiesel segment coupled with an increase in corn ground from 4.3 million bushels during the fourth quarter of 2022 to 5.2 million bushels during the fourth quarter of 2023 offset by a 33% decrease in the average delivered cost of corn.

Gross profit for the fourth quarter of 2023 was $864 thousand, compared to a gross loss of $1.1 million during the same period in 2022.

Selling, general and administrative expenses rose from $7.5 million during the fourth quarter of 2022 to $9.8 million during the fourth quarter of 2023.

Operating loss was $9.0 million for the fourth quarter of 2023, compared to an operating loss of $8.7 million during the fourth quarter of 2022.

Net loss was $25.4 million for the fourth quarter of 2023, compared to a net loss of $22.4 million for the fourth quarter of 2022.

Cash at the end of the fourth quarter of 2023 was $2.7 million, compared to $4.3 million at the end of the fourth quarter of 2022.

Financial Results for the Twelve Months Ended December 31, 2023

Revenues were $187 million for the twelve months ended December 31, 2023, compared to $257 million for 2022. During 2023, $77.2 million revenues were generated by the India Biodiesel segment and $5.5 million revenues were generated by the California Renewable Natural Gas segment, and $104.3 million revenues were generated by the California ethanol segment due to the extended maintenance cycle at the Keyes ethanol plant which allowed for the acceleration of the implementation of several important ethanol plant efficiency upgrades during the historically high natural gas prices.

Cost of Goods Sold decreased from $262 million during the twelve months ended December 31, 2022 to $185 million during the same period in 2023 following the revenue changes during 2023. In addition, delivered corn cost decreased from an average of $9.65 per bushel during the twelve months of 2022 to $7.11 per bushel during the twelve months of 2023.

Gross profit for the twelve months ended December 31, 2023 was $2.0 million, compared to a gross loss of $5.5 million during the same period in 2022. Our India Biodiesel segment accounted for $9.0 million of gross profit from sales of biodiesel for the year ended December 31, 2023.

Selling, general and administrative expenses increased to $39.3 million during the twelve months ended December 31, 2023, compared to $28.7 million during the same period in 2022 primarily attributable to the stock compensation of $5.0 million and the reclassification of expenses from cost of goods sold during the extended maintenance cycle of the Keyes plant.

Operating loss was $37.4 million for the twelve months ended December 31, 2023, compared to an operating loss of $34.4 million for the same period in 2022, with the Keyes Plant only operating for 7 months in 2023

Interest expense was $39.5 million during the year ended December 31, 2023, excluding accretion and other expense of Series A preferred units in our Aemetis Biogas LLC subsidiary, compared to interest expense of $28.8 million during the year ended December 31, 2022. Additionally, our Aemetis Biogas LLC subsidiary recognized $25.3 million of accretion and debt extinguishment costs in connection with redemption liabilities on its preferred stock during the year ended December 31, 2023, compared to $59.3 million during the same period in 2022.

Net loss was $46.4 million for the twelve months ended December 31, 2023, compared to a net loss of $107.8 million during the same period in 2022.

Cash at the end of the fourth quarter of 2023 was $2.7 million compared to $4.3 million at the end of the twelve months ended December 31, 2022. Investments in our low carbon initiatives increased property, plant and equipment by $33 million while debt repayments of $51.3 million were made to our senior lender during the twelve months ended December 31, 2023.

About Aemetis

Headquartered in Cupertino, California, Aemetis is a renewable natural gas, renewable fuel and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace petroleum-based products and reduce greenhouse gas emissions. Founded in 2006, Aemetis is operating and actively expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas. Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis owns and operates a 60 million gallon per year production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. Aemetis is developing the sustainable aviation fuel (SAF) and renewable diesel fuel biorefinery in California to utilize renewable hydrogen, hydroelectric power, and renewable oils to produce low carbon intensity renewable jet and diesel fuel. For additional information about Aemetis, please visit www.aemetis.com.

NON-GAAP FINANCIAL INFORMATION

We have provided non-GAAP measures as a supplement to financial results based on GAAP. A reconciliation of the non-GAAP measures to the most directly comparable GAAP measures is included in the accompanying supplemental data. Adjusted EBITDA is defined as net income/(loss) plus (to the extent deducted in calculating such net income) interest expense, loss on debt extinguishment, loss on lease termination, USDA cash grants, income tax expense or benefit, intangible and other amortization expense, accretion expense, depreciation expense, gain on litigation, loss on impairment of intangibles and share-based compensation expense.

Adjusted EBITDA is not calculated in accordance with GAAP and should not be considered as an alternative to net income/(loss), operating income or any other performance measures derived in accordance with GAAP or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA is presented solely as a supplemental disclosure because management believes that it is a useful performance measure that is widely used within the industry in which we operate. In addition, management uses Adjusted EBITDA for reviewing financial results, for budgeting and planning purposes and as a non-GAAP liquidity measure. Adjusted EBITDA measures are not calculated in the same manner by all companies and, accordingly, may not be an appropriate measure for comparison between companies.

Safe Harbor Statement

This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements relating to our five-year growth plan; trends in market conditions with respect to prices for inputs for our products versus prices for our products; our ability to fund, develop, build, maintain and operate digesters, facilities and pipelines for our Dairy Renewable Natural Gas segment; our ability to fund, develop and operate our Sustainable Aviation Fuel, Renewable Diesel, and Carbon Capture and Sequestration projects, including obtaining required permits; our ability to receive awarded grants by meeting all of the required conditions, including meeting the minimum contributions; our ability to fund, develop and operate our sustainable aviation fuel and renewable biodiesel projects; our intention to repurchase the Series A preferred units relating to our Aemetis Biogas subsidiary and the expected valuation premium thereof; and our ability to raise additional capital. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “view,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other filed documents. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

External Investor Relations Contact:

Kirin Smith

PCG Advisory Group

(646) 863-6519

ksmith@pcgadvisory.com


Company Contact:

Todd Waltz

Chief Financial Officer

(408) 213-0925

twaltz@aemetis.com


(Tables follow)


AEMETIS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except per share data)

  For the three months ended December 31,  For the years ended December 31, 
  2023  2022  2023  2022 
Revenues $70,764  $66,732  $186,717  $256,513 
Cost of goods sold  69,900   67,864   184,700   262,048 
Gross profit (loss)  864   (1,132)  2,017   (5,535)
                 
Research and development expenses  37   41   152   180 
Selling, general and administrative expenses  9,786   7,520   39,266   28,686 
Operating loss  (8,959)  (8,693)  (37,401)  (34,401)
                 
Other expense (income):                
Interest expense                
Interest rate expense  8,869   6,588   32,995   21,407 
Debt related fees and amortization expense  1,792   2,164   6,524   7,363 
Accretion and other expenses of Series A preferred units  5,125   3,968   25,313   9,888 
Loss on debt extinguishment  -   -   -   49,386 
Other income  (57)  (43)  (2,077)  (15,740)
Loss before income taxes  (24,688)  (21,370)  (100,156)  (106,705)
Income tax expense (benefit)  754   1,040   (53,736)  1,053 
Net loss $(25,442) $(22,410) $(46,420) $(107,758)
                 
Net loss per common share                
Basic $(0.64) $(0.63) $(1.22) $(3.12)
Diluted $(0.64) $(0.63) $(1.22) $(3.12)
                 
Weighted average shares outstanding                
Basic  39,674   35,302   38,061   34,585 
Diluted  39,674   35,302   38,061   34,585 


AEMETIS, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(In thousands)

  As of
December 31,
 
  2023  2022 
Assets        
Current assets:        
Cash and cash equivalents $2,667  $4,313 
Accounts receivable  8,633   1,264 
Inventories  18,291   4,658 
Prepaid and other current assets  6,809   7,901 
Total current assets  36,400   18,136 
         
Property, plant and equipment, net  195,108   180,441 
Other assets  11,898   8,537 
Total assets $243,406  $207,114 
         
Liabilities and stockholders' deficit        
Current liabilities:        
Accounts payable $32,132  $26,168 
Current portion of long term debt  13,585   12,465 
Short term borrowings  23,443   36,754 
Mandatorily redeemable Series B convertible preferred stock  4,521   4,082 
Other current liabilities  10,708   8,812 
Total current liabilities  84,389   88,281 
         
Total long term liabilities  375,994   320,687 
         
Stockholders' deficit:        
Series B convertible preferred stock  -   1 
Common stock  41   36 
Additional paid-in capital  264,058   232,546 
Accumulated deficit  (475,405)  (428,985)
Accumulated other comprehensive loss  (5,671)  (5,452)
Total stockholders' deficit  (216,977)  (201,854)
Total liabilities and stockholders' deficit $243,406  $207,114 


RECONCILIATION OF ADJUSTED EBITDA TO NET INCOME / (LOSS)
(In thousands, unaudited)

  For the three months ended December 31,  For the years ended December 31, 
EBITDA Calculation 2023  2022  2023  2022 
                 
Net loss  (25,442)  (22,410)  (46,420)  (107,758)
Adjustments                
Interest expense  10,661   8,752   39,519   28,770 
Depreciation expense  1,725   1,496   6,933   5,535 
Accretion of Series A preferred units  5,125   3,968   25,313   9,888 
Share-based compensation  1,437   1,476   7,660   6,410 
Intangibles and other  36   12   72   46 
Loss on debt extinguishment  -   -   -   49,386 
Loss on lease termination  -   -   -   736 
USDA cash grants  -   -   (1,774)  (14,100)
Gain on litigation  -   -   -   (1,400)
Income tax expense (benefit)  754   1,040   (53,736)  1,053 
Total adjustments  19,738   16,744   23,987   86,324 
                 
Adjusted EBITDA  (5,704)  (5,666)  (22,433)  (21,434)


PRODUCTION AND PRICE PERFORMANCE
(unaudited)

  Three Months ended December 31,  Years ended December 31, 
  2023  2022  2023  2022 
Ethanol                
Gallons sold (in millions)  15.0   13.4   32.1   59.0 
Average sales price/gallon $2.20  $2.65  $2.44  $2.81 
Percent of nameplate capacity  109%  98%  58%  107%
WDG                
Tons sold (in thousands)  102.6   90.0   225.3   396.9 
Average sales price/ton $97  $125  $97  $128 
Delivered Cost of Corn                
Bushels ground (in millions)  5.2   4.3   11.5   20.2 
Average delivered cost / bushel $6.70  $10.05  $7.11  $9.65 
Dairy Renewable Natural Gas                
MMBtu external sales (in thousands)  52.2   8.4   194.2   8.4 
MMBtu stored as inventory (in thousands)  68.0   9.0   68.0   9.0 
MMBtu intercompany sales (in thousands)  -   4.4   -   48.6 
Biodiesel                
Metric tons sold (in thousands)  18.3   10.7   60.5   17.7 
Average Sales Price/Metric ton $1,157  $1,511  $1,232  $1,526 
Percent of Nameplate Capacity  49%  29%  40%  12%
Refined Glycerin                
Metric tons sold (in thousands)  1.3   1.2   4.2   1.2 
Average Sales Price/Metric ton $616  $845  $640  $850 


FAQ

What was Aemetis, Inc.'s (AMTX) annual sales figure for the India biodiesel segment?

Aemetis, Inc. reported $77.2 million in annual sales from the India biodiesel segment, a significant 175% increase over the prior year.

What was Aemetis, Inc.'s (AMTX) total revenue for 2023?

Aemetis, Inc.'s total revenue for 2023 was $186.7 million, driven by growth in the biodiesel and renewable natural gas segments.

What was the revenue for the fourth quarter of 2023?

The revenue for the fourth quarter of 2023 was $70.8 million, showcasing an increase from the same period in 2022.

What were some key financial highlights for Aemetis, Inc. (AMTX) in 2023?

Key financial highlights for Aemetis in 2023 include the repayment of $50.2 million of debt, positive cash flow of $32.7 million, and progress in various projects outlined in the Five Year Plan.

What percentage increase did Aemetis achieve in annual sales from the India biodiesel segment?

Aemetis achieved a remarkable 175% increase in annual sales from the India biodiesel segment compared to the prior year.

Aemetis, Inc. (DE)

NASDAQ:AMTX

AMTX Rankings

AMTX Latest News

AMTX Stock Data

175.12M
38.53M
10.14%
25.08%
12.49%
All Other Miscellaneous Chemical Product and Preparation Manufacturing
Manufacturing
Link
United States of America
CUPERTINO

About AMTX

headquartered in cupertino, california, aemetis is an advanced renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of second-generation ethanol and biodiesel plants into advanced biorefineries. founded in 2006, aemetis owns and operates a 60 million gallon per year ethanol production facility in california’s central valley, near modesto. aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the east coast of india producing high quality distilled biodiesel and refined glycerin for customers in india, the us and europe. aemetis operates a research and development laboratory at the maryland biotech center, and holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. for additional information about aemetis, please visit